Olmesartan Medoxomil Tablet
Description
OLMEROOT
Olmesartan Medoxomil 40 mg Tablets
Division: DIABGLYM
Composition
Each tablet contains:
Olmesartan Medoxomil IP — 40 mg
Excipients — q.s.
Colour: Approved colour used
Dosage form: Oral tablet
Product Description
OLMEROOT contains Olmesartan Medoxomil 40 mg, a potent angiotensin II receptor blocker (ARB) formulated for the effective management of hypertension and long-term cardiovascular and renal protection. Olmesartan provides sustained blood pressure control by selectively blocking the angiotensin II AT1 receptor, resulting in vasodilation, reduced peripheral vascular resistance, and decreased aldosterone-mediated sodium retention.
Olmesartan Medoxomil is widely prescribed in cardiology, nephrology, and internal medicine for patients with essential hypertension, diabetes-associated hypertension, chronic kidney disease, metabolic syndrome, and high cardiovascular risk. It helps reduce systolic and diastolic blood pressure, improve vascular function, and lower the risk of stroke, myocardial infarction, heart failure, and progressive renal damage.
OLMEROOT is particularly beneficial for patients requiring intensive blood pressure control, once-daily antihypertensive therapy, and comprehensive cardiovascular and renal protection.
Technical Knowledge of Olmesartan Medoxomil
Olmesartan Medoxomil is a prodrug that is rapidly converted to the active metabolite Olmesartan after oral administration. Olmesartan selectively blocks angiotensin II type 1 (AT1) receptors, preventing angiotensin II-mediated vasoconstriction, aldosterone secretion, sympathetic activation, and vascular remodeling.
Unlike ACE inhibitors, ARBs do not inhibit bradykinin metabolism, which contributes to a lower incidence of cough and angioedema. Olmesartan has a long duration of action, allowing effective once-daily dosing and sustained 24-hour blood pressure control.
Mechanism of Action
Olmesartan selectively blocks AT1 receptors, prevents angiotensin II-mediated vasoconstriction, reduces aldosterone secretion, decreases peripheral vascular resistance, lowers blood pressure, improves vascular compliance, and provides cardiovascular and renal protection.
Key Benefits
Effective reduction of systolic and diastolic blood pressure
Provides sustained 24-hour blood pressure control
Supports cardiovascular and renal protection
Improves vascular function and endothelial health
Reduces arterial stiffness
Helps prevent stroke and myocardial infarction
Suitable for diabetic and chronic kidney disease patients
Convenient once-daily dosing
Suitable for long-term hypertension management under medical supervision
Clinical Applications
OLMEROOT is commonly prescribed for essential hypertension, uncontrolled hypertension, hypertension with diabetes mellitus, hypertension with chronic kidney disease, metabolic syndrome, cardiovascular risk reduction, diabetic nephropathy, and long-term antihypertensive management.
Facts About Olmesartan Medoxomil
Olmesartan is a highly selective ARB with strong antihypertensive efficacy and extensive clinical evidence supporting cardiovascular and renal protection. It is widely recommended in international hypertension guidelines and is particularly valuable in patients with diabetes, chronic kidney disease, and high cardiovascular risk because of its excellent blood pressure control and target organ protective effects.
Key Facts
Potent angiotensin II receptor blocker (ARB)
Olmesartan Medoxomil 40 mg for intensive blood pressure control
Provides sustained 24-hour antihypertensive action
Supports cardiovascular and renal protection
Effective in diabetic and chronic kidney disease patients
Evidence-based ARB therapy
Quality-assured pharmaceutical formulation
PCD Pharma Franchise Opportunity
OLMEROOT is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, chronic kidney disease, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this formulation.
Why Choose OLMEROOT for PCD Pharma Franchise?
High prescription potential
Strong physician and cardiologist acceptance
Attractive monopoly franchise opportunity
Competitive pricing
Promotional support available
Visual aids and marketing inputs
Consistent product quality
Excellent repeat business potential
Third Party Manufacturing
Chemsroot Pharmaceutical offers Third Party Manufacturing of Olmesartan Medoxomil 40 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.
Our Third Party Manufacturing Services Include
Private label manufacturing
Contract manufacturing
Custom brand manufacturing
Loan license manufacturing
DCGI-compliant production
GMP-certified manufacturing
Batch manufacturing documentation
Product registration support
Customized packaging and artwork
Monopoly franchise packaging
Bulk manufacturing capability
Manufacturing Features
Pharmaceutical-grade raw materials
IP/BP/USP quality standards
In-process quality control
Finished product testing
Stability-oriented formulation
Moisture-controlled tablet manufacturing
Blister and Alu-Alu packaging options
OLMEROOT from DIABGLYM combines effective blood pressure control, comprehensive cardiovascular and renal protection, evidence-based ARB therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Olmesartan formulation.
